NATCAPSUQ

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLAB
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)106.9593.0993.09
Receivable Days (DSO)134.26139.12139.12
Payable Days (DPO)161.78195.61185.99
Cash Conversion Cycle (days)79.4336.6046.22
Working Capital Turnover5.7245.9946.86
Asset Turnover0.400.440.44
Cash Conversion (CFO/Net Income)43.33-0.44-0.44
CFO/EBITDA1.53-7.00-7.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.